Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P9T4 | ISIN: US8112922005 | Ticker-Symbol: 135A
Tradegate
31.10.24
19:30 Uhr
1,248 Euro
-0,003
-0,24 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SCYNEXIS INC Chart 1 Jahr
5-Tage-Chart
SCYNEXIS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2301,29013:04
1,2211,28001.11.

Aktuelle News zur SCYNEXIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.10.SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit2
03.10.SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 20242
16.09.Scynexis CEO acquires $27,400 in company stock6
10.09.SCYNEXIS INC - 8-K, Current Report2
05.09.SCYX stock touches 52-week low at $1.35 amid market challenges5
27.08.SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference2
09.08.SCYNEXIS GAAP EPS of -$0.30 misses by $0.104
08.08.SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update155Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to...
► Artikel lesen
08.08.SCYNEXIS INC - 10-Q, Quarterly Report1
23.07.SCYNEXIS To Receive $10 Mln Milestone Payment From GSK For Completed Clinical Study Report312LONDON (dpa-AFX) - SCYNEXIS Inc. (SCYX) announced it will receive a $10 million development milestone payment from GSK under their license agreement for ibrexafungerp. The milestone payment...
► Artikel lesen
23.07.SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports5
20.06.SCYNEXIS INC - 8-K, Current Report2
20.06.SCYNEXIS INC - S-8, Securities to be offered to employees in employee benefit plans2
08.05.SCYNEXIS GAAP EPS of $0.01 beats by $0.20, revenue of $1.37M beats by $1.07M3
08.05.SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update358SCY-247's IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024Clinical study reports for the FURI, CARES and NATURE trials in refractory...
► Artikel lesen
08.05.SCYNEXIS INC - 10-Q, Quarterly Report1
30.04.SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)151In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a broad range of pathogenic fungi, including...
► Artikel lesen
28.03.SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update246SCY-247's IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study...
► Artikel lesen
13.11.23Scynexis: SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update452IND enabling development activities for SCY-247, the next generation fungerp from SCYNEXIS' proprietary antifungal platform, continue to advanceRemediation strategies following the voluntary recall...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1